Stock Scorecard
Stock Summary for Terns Pharmaceuticals Inc (TERN) - $7.42 as of 10/24/2025 6:35:25 PM EST
Total Score
10 out of 30
Safety Score
37 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for TERN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TERN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TERN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TERN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TERN (37 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 4 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for TERN
Financial Details for TERN
Company Overview |
|
|---|---|
| Ticker | TERN |
| Company Name | Terns Pharmaceuticals Inc |
| Country | USA |
| Description | Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Foster City, California, focused on developing innovative small-molecule therapies aimed at treating nonalcoholic steatohepatitis (NASH) and other serious chronic liver diseases. With a robust pipeline of both single-agent and combination therapy candidates, Terns is at the forefront of addressing unmet medical needs in hepatology. The company’s commitment to advancing its clinical programs positions it as a key player in the biopharmaceutical landscape, potentially offering significant value to investors as it works towards bringing its therapies to market. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/18/2025 |
Stock Price History |
|
| Last Day Price | 7.42 |
| Price 4 Years Ago | 7.07 |
| Last Day Price Updated | 10/24/2025 6:35:25 PM EST |
| Last Day Volume | 2,044,830 |
| Average Daily Volume | 1,328,079 |
| 52-Week High | 9.03 |
| 52-Week Low | 1.86 |
| Last Price to 52 Week Low | 298.92% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.95 |
| Sector PE | 41.12 |
| 5-Year Average PE | -6.61 |
| Free Cash Flow Ratio | 4.44 |
| Industry Free Cash Flow Ratio | 14.54 |
| Sector Free Cash Flow Ratio | 31.25 |
| Current Ratio Most Recent Quarter | 24.70 |
| Total Cash Per Share | 1.67 |
| Book Value Per Share Most Recent Quarter | 3.49 |
| Price to Book Ratio | 2.30 |
| Industry Price to Book Ratio | 29.98 |
| Sector Price to Book Ratio | 32.29 |
| Price to Sales Ratio Twelve Trailing Months | 302.64 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 16.43 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 87,511,000 |
| Market Capitalization | 649,331,620 |
| Institutional Ownership | 104.28% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 1.50% |
| Reported EPS 12 Trailing Months | -1.03 |
| Reported EPS Past Year | -0.52 |
| Reported EPS Prior Year | -1.13 |
| Net Income Twelve Trailing Months | -91,745,000 |
| Net Income Past Year | -88,853,000 |
| Net Income Prior Year | -90,210,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 145,966,000 |
| Total Cash Past Year | 161,439,000 |
| Total Cash Prior Year | 79,926,000 |
| Net Cash Position Most Recent Quarter | 144,933,000 |
| Net Cash Position Past Year | 161,439,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 544,000 |
| Total Debt Most Recent Quarter | 1,033,000 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 345,870,000 |
| Total Stockholder Equity Prior Year | 255,367,000 |
| Total Stockholder Equity Most Recent Quarter | 305,229,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -74,359,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.85 |
| Free Cash Flow Past Year | -70,058,000 |
| Free Cash Flow Prior Year | -67,442,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.32 |
| MACD Signal | 0.32 |
| 20-Day Bollinger Lower Band | 3.34 |
| 20-Day Bollinger Middle Band | 6.38 |
| 20-Day Bollinger Upper Band | 9.41 |
| Beta | -0.04 |
| RSI | 60.99 |
| 50-Day SMA | 5.05 |
| 150-Day SMA | 6.82 |
| 200-Day SMA | 6.11 |
System |
|
| Modified | 10/23/2025 10:45:06 AM EST |